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Abstract Celiac disease is characterized by a chronic in-
flammatory reaction in the intestine and is triggered by
gluten, a constituent derived from grains which is present
in the common daily diet in the Western world. Despite
decades of research, the mechanisms behind celiac disease
etiology are still not fully understood, although it is clear
that both genetic and environmental factors are involved. To
improve the understanding of the disease, the genetic com-
ponent has been extensively studied by genome-wide
association studies. These have uncovered a wealth of in-
formation that still needs further investigation to clarify its
importance. In this review, we summarize and discuss the
results of the genetic studies in celiac disease, focusing on
the “non-HLA” genes. We also present novel approaches to
identifying the causal variants in complex susceptibility loci
and disease mechanisms.
Keywords Celiac disease . Autoimmune disease . Immune-
related disease . Genome-wide association studies . GWAS .
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Introduction
Immune-related diseases range from autoimmune diseases
such as celiac disease (CD), rheumatoid arthritis (RA),
multiple sclerosis (MS), and type I diabetes (T1D), to more
chronic inflammatory disorders such as asthma and inflam-
matory bowel disease (IBD). Together these disorders now
account for 5–10 % of all disease cases in Western countries
(see elsewhere in this issue).
Celiac disease is one of the best-understood immune-
related diseases. It is the most common food intolerance in
humans, affecting at least 1 % of the Western population. It
is a multifactorial disease caused by many different genetic
factors that act in concert with non-genetic causes. A genetic
association between CD and the HLA class II genes in the
major histocompatibility complex (MHC) was documented
almost 40 years ago [1]. One of the most important trigger-
ing factors is dietary gluten, a storage protein present in
wheat and related grains (hordein in barley, secalin in rye,
and avedin in oats) (see elsewhere in this issue).
CD is an excellent model for studying the contribution of
genetic factors to immune-related disorders because: (1) the
environmental triggering factor is known (gluten), (2) as in
other autoimmune diseases, specific HLA types (HLA-
DQA1 and HLA-DQB1 in the case of CD) are critically
involved (see elsewhere in this issue), (3) there is involve-
ment of non-HLA disease-susceptibility loci, many of which
are shared with other autoimmune diseases, (4) there is an
elevated incidence of other immune-related diseases both in
family members and individuals, and (5) both the innate and
the adaptive immune responses play a role in CD [2].
Prior to genome-wide association studies (GWAS) the
genetics of CD included candidate gene studies in case-
control cohorts and linkage studies in multi-generation fam-
ilies and affected sibpairs [3]. None of these studies have
convincingly resulted in the identification of genetic factors
beyond the well-established HLA-DQA1 and HLA-DQB1
genes. With the introduction of GWAS, the number of
genetic factors implicated in CD has increased and 54 %
of its heritability can now be explained. However, the
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methods for calculating the heritability are currently under
debate [4], but CD remains the immune-related disorder
with the best-characterized genetic component (e.g., MS
20 %, RA 16 %, CrD 23 %, UC 16 %, T1D 45 %) [5, 6].
GWAS in CD: yielding only the tip of the iceberg
GWA studies provide an unbiased approach for identifying
genes and pathways involved in a certain phenotype, as they
are not based on prior biological knowledge of the genes
that they identify. Indeed, GWAS frequently identify genes
and/or pathways that were not previously implicated in the
phenotype of interest, for example, the unexpected role of
the autophagy pathway in IBD [7]). Such an unbiased
approach is highly beneficial as it generates new hypotheses
that open up new avenues for investigation. Nevertheless,
we must be careful in interpreting GWAS findings, as it is
sometimes difficult to pinpoint the primary target of the
genetic association. It is important to realize that the gene
names of disease-associated loci are merely signposts. Often
it is difficult to identify the single gene or gene variant
providing risk or protection to a disease, because disease-
associated loci often contain multiple genes and potential
risk variants. Since individual genetic risk variants are usu-
ally common and have only a modest effect on disease risk,
and because the cell or a sample of the tissue where the
disease manifests is difficult to obtain for research purposes,
it is difficult to investigate the consequence of the true
causal risk variant. Despite these hurdles, GWAS have un-
covered hundreds of loci associated to immune-related dis-
orders, although these may represent only the tip of the
iceberg [8–10]. This wealth of information will serve to
formulate hypotheses that can be tested using experimental
studies. Moreover, GWAS data can also be subjected to
bioinformatic analysis to obtain more details about the tip
of the iceberg and to reveal what still remains under the
surface (see later sections in this review). To appreciate the
complexity of GWAS, it is important to fully grasp the
statistics involved. The interested reader can find an exten-
sive description of the analytical methods in a review by
Balding [11]. Here, we will describe how GWAS have
contributed to our understanding of the genetics of CD.
The first GWAS for CD was performed in 2007 on a
relatively small cohort consisting of 778 CD patients and
1,422 controls, all from the UK [12]. The subjects were
tested for association to some 300,000 genetic variants in
the human genome (so-called single nucleotide polymor-
phisms or SNPs) and the top 1,500 most associated SNPs
were followed-up in replication cohorts consisting of 1,643
cases and 3,406 controls. Besides HLA, 13 regions in the
genome were identified as harboring genes and genetic
variants associated to CD [12–14]. Interestingly, the
majority of the identified regions contained genes control-
ling immune responses, such as the IL2-IL21 locus on 4q27,
thereby suggesting, for the first time, the potential role of
IL2, a cytokine important for the homeostasis and function
of T cells, and of IL21, a new member of the type 1 cytokine
superfamily which regulates many other immune and non-
immune cells. This first GWA study also revealed the phe-
nomena of pleiotropy, i.e., genetic variants associated to CD
are also associated with other immune-related diseases. For
example, the IL2-21 locus is now a well-established disease
susceptibility locus for T1D, RA, UC, MS, and systemic
lupus erythematosus (SLE) [2, 15–22].
A much larger GWAS on CD included more than 4,500
CD patients and nearly 11,000 controls from four different
populations (UK, Italy, Finland, the Netherlands) and
550,000 SNPs [23]. After replicating the most-significant
131 SNPs in seven follow-up cohorts of European descent,
comprising almost 5,000 CD patients and more than 5,500
controls, 13 new regions in the genome were found to be
associated with CD, bringing the total number of non-HLA
associated loci to 26. The study by Dubois et al. [23] also
showed that about 50 % of CD-associated SNPs affect the
expression of nearby genes (so-called expression quantita-
tive traits loci or eQTLs), indicating that the mechanism
underlying CD is governed by a deregulation of gene
expression.
More recently, the number of loci associated to CD was
raised to 39 [24] when the Immunochip platform became
available [25] (see fine-mapping approaches).
The “resolution” of GWAS heavily depends on the num-
ber of samples included. One way to circumvent this limi-
tation is to combine datasets and to perform a meta-analysis,
as was done by Dubois et al. [23]. Given the pleiotropic
nature of the genetics underlying immune-related diseases,
it also became possible to conduct cross-disease meta-
analyses aimed at identifying additional shared susceptibil-
ity loci, as has been successfully demonstrated for CD. Two
published GWAS datasets, one on CD [23] and one on RA
[16], were pooled and the data obtained from the primary
analysis was replicated using 2,169 CD cases (and 2,255
controls) and 2,845 RA cases (and 4,944 controls). In this
meta-analysis, eight SNPs were replicated, including
four SNPs mapping to loci that had not previously been
associated with either disease (CD247, UBEL3, DDX6, and
UBASH3A) and another four SNPs mapping to loci that had
previously only been established in one of the diseases
(SH2B3, 8q24.2, STAT4, and TRAF1-C5). The identification
of these eight loci, together with six known loci (MMEL1/
TNFRSF14, REL, ICOS/CTLA4, IL2/IL21, TNFAIP3, and
TAGAP), brought the total number of non-HLA susceptibil-
ity loci shared between CD and RA to 14 [17]. A similar
study was performed for CD and CrD and identified four
shared susceptibility loci [21]. Although meta-analysis can
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help identify shared risk loci, it is important to realize that it
is also possible to obtain contradictory data. Sometimes the
association to the same loci is more complex and observed
with different SNPs, or with identical SNPs but with the
opposite allele. For example, the A allele of SNP rs917997
in IL18RAP is increased in frequency in CD cases, while the
same allele is decreased in frequency in T1D patients [26].
This could mean that the SNP is protective in one disease
and a risk factor in the other.
Fine-mapping approaches
One of the problems associated with GWAS is that the
genome is not necessarily covered at a high resolution.
The early GWAS chips used in CD studies contained
300,000–550,000 SNPs, while the human genome consists
of 3 billion basepairs, of which at least 1-2 % is poly-
morphic in any given individual. Many loci are therefore
not covered densely enough with SNPs, resulting in the
association with disease of regions that can contain multiple
genes. This complicates the interpretation of the GWAS
results, but one of the most straightforward approaches to
address this problem is to fine-map disease-associated loci
by zooming in on specific collections of SNPs that cover
defined gene-sets at high density. A recent genetic study
aimed at fine-mapping CD GWAS loci was performed on
the Immunochip platform [24]. The Immunochip [25] is a
custom Illumina Infinium HD array, which was specifically
designed by the Immunochip Consortium to densely fine-
map existing GWAS loci and to replicate loci that had not
yet reached genome-wide significance. The approximately
200,000 SNPs on the Immunochip array consist of SNP
variants that were present in public databases at the time
of production (September 2009), including variants de-
scribed in the European samples sequenced as part of the
1000 Genomes Project pilot phase I. The Immunochip cov-
ers: (1) the 186 loci associated with autoimmune or inflam-
matory diseases meeting genome-wide significance criteria
(P<5×10−8), from 12 immune-mediated diseases (autoim-
mune thyroid disease, ankylosing spondylitis, CD, CrD, IgA
deficiency, MS, primary biliary cirrhosis, psoriasis, RA, SLE,
T1D, and UC), (2) the MHC and KIR/LILR loci, (3) the most
significant SNPs from GWAS loci with sub-significant P
values awaiting deep replication, and (4) a small proportion
of SNPs of investigator-specific undisclosed content. In the
case of CD, the Immunochip was used to genotype more than
12,000 CD patients and a similar number of controls from
seven different populations [24]. The platform revealed a total
of 39 genome-wide significant loci (Fig. 1a), but upon condi-
tional analysis 13 loci were found to include more than one
independent association signal, resulting in a total of 57 inde-
pendent non-HLA signals. These 57 SNPs are in general
rather common, with frequencies above 5% andmodest effect
sizes with an odds ratio between 1.124 and 1.360 (compared
to an odds ratio of >5 for HLA) (Fig. 1b). Because of the
higher density of SNPs for each of the loci, it was possible to
refine the association signal to a single gene for 29 loci
(Fig. 1a).
One of the most surprising findings from this fine-
mapping study was the observation that the PTPRK gene
is the causal gene in the THEMIS/PTPRK locus [23]. Im-
munological publications on the function of the THEMIS
gene had suggested that it could be a very interesting can-
didate risk gene for CD, as it is an important regulator of
thymic T cell selection [27]. This observation suggested an
important role for the thymus; this is an attractive theory
given the lack of oral tolerance present in CD. However,
there is only limited literature on the PTPRK gene, but
knock-out of the Ptprk gene in rats leads to a Th cell
deficiency [28]. This example shows that GWAS results
can easily be misinterpreted if attractive candidates are
chosen without performing further validation. Immunochip
analysis also identified 147 non-CD autoimmune disease
loci with intermediate p values (in GWAS only SNPs with
a P<5×10−8 are considered true associations as they have
reached “genome-wide significance”). It cannot be ruled out
that these SNPs play a role in the disease process but that the
study was underpowered to unequivocally prove involve-
ment of these SNPs, suggesting that there might be dozens
more genes contributing to CD.
Another approach for fine-mapping is imputation [29, 30].
Imputation is an in silico process in which the allelic combi-
nations of non-genotyped SNPs in an individual are inferred
(though not directly assayed) based on the haplotype structure
present in large reference datasets, such as the ones provided
by the 1000 Genomes Project (2010) and the International
HapMap project [31–33]. A haplotype is the combination of
alleles at adjacent locations (loci) on the chromosome that are
transmitted together. After imputation, each dataset typically
contains information on 2.5–4 million SNP variants per indi-
vidual, including low-frequency variants that are not covered
on a typical GWAS array [34]. Subsequent association analysis
on imputed genotypes may narrow down the region of associ-
ation and help pinpoint the causative variant. As imputation is
merely an in silico prediction of unknown genotypes based on
the haplotype structure of a reference population, sufficient
quality control measures are needed to exclude badly imputed
SNPs and then the predicted genotypes need to be validated by
other genotyping techniques or direct sequencing.
Genetic architecture of celiac disease
The studies conducted thus far (Fig. 2) suggest that the
genetic architecture of CD follows the common disease-
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HCFC1, TMEM187, IRAK1 1.18 --
UBE2L3, YDJC 1.16 RA, SLE
ICOSLG 0.89 UC, CrD
UBASH3A 0.88 T1D, VL, RA
PTPN2 1.17 T1D, CrD, RA
SOCS1, PRM1, PRM2 0.92 --
CIITA and others 1.14 UC
CLK3 and others 1.13 --
ZFP36L1 1.13 CrD, MS
SH2B3, ATXN2 1.19 T1D, RA
SLE1.18E1ST
TREH, DDX6 0.86 RA
POU2AF1 and others 1.16 --
ZMIZ1 0.86 MS, IBD, VL, CrD
PFKFB3, PRKCQ 0.88 RA, T1D
PVT1 0.91 MS
ELMO1 1.18 --
TAGAP 1.16 CrD, MS
OLIG3, TNFAIP3 1.29 RA, SLE, PSO
PTPRK 1.21 MS
BACH2 1.10 T1D, CrD, MS
IRF4 0.89 --
KIAA1109, ADAD1, IL2, IL21 0.71 T1D, RA, AA, UC
LPP 0.76 VL
SCHIP1, IL12A 1.36 PBC, MS
ARHGAP31 1.11 --
CCR1-3, LTF 1.20 --
CCR4, GLB1 1.11 --
CD28, CTLA4, ICOS 1.19 T1D, RA, AA, GD
STAT4 0.79 SLE, RA, PBC
UBE2E3, ITGA4 1.16 --
IL18R1, IL18RAP 1.20 CrD
PLEK, FBX048 0.92 MS
PUS10 1.17 UC, CrD
C1orf106 0.89 UC, MS
RGS1 0.77 MS
FASLG, TNFSF18 0.87 --
RUNX3 0.92 ASP
C1orf93, MMEL1, TTC34 0.87 RA, UC
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common variant (CD-CV) hypothesis [35–37]. To date,
approximately 54 % of the genetics of CD can be explained
by HLA plus the 57 non-HLA SNPs. The CD-CV hypoth-
esis suggests that the remainder of the CD iceberg will also
consist of common variants with very small effect sizes.
Since identifying more of these variants would require ex-
tremely large cohort sizes, this would be very difficult to
realize. There are several reasons why it is conceivable that
the design of the current studies inhibits identification of less
common genetic variants (with allele frequencies between
1–5 %): (1) the GWAS genotyping platforms are skewed
towards covering common variants; (2) rare variants tend to
be more population-specific but the studies conducted with
the Immunochip for instance—which does contain low-
frequency variants—did not take separate populations into
account, thereby probablymissing population-specific effects.
The ultimate way to identify low frequency (allele frequency
1–5 %) and rare variants (allele frequency <1 %) requires
different technologies, such as deep sequencing. The advent
of whole genome sequencing is expected to reveal much of
the landscape of rare variation [38], but for large population
studies this approach is currently still too expensive. Another
option is testing for the existence of rare variants with high
effect sizes, but this requires a different strategy. Each popu-
lation should be investigated separately for the disease-
associated haplotype, which then needs to be resequenced to
identify all the possible variants on it. However, the CD
GWAS cohorts studied so far mostly consisted of populations
of European descent, which limits the variation in predispos-
ing haplotypes. To capture the vast majority of potential
disease-causing rare variants would thus require as many
different (multi-ethnic) CD cohorts as possible. Comparing
haplotypes across different populations also has some addi-
tional advantages and may result in even more refinement
of established association signals or help in identifying
population-specific risk haplotypes/variants. For example,
genotyping tag-SNPs at TNFAIP3, one of the autoimmune
risk loci, in an African-American SLE cohort revealed a novel
African-derived risk haplotype that was in linkage disequilib-
rium (LD) with a non-synonymous coding SNP [39], whereas
in another study [40] re-sequencing of the same region in
Europeans and Koreans revealed a deletion of T, followed
by a T > A transversion in a non-coding region that showed
much stronger odds ratio in Koreans than Europeans for SLE
(odds ratio 0 2.54 versus 1.7 in Europeans). Thus, the use of
multi-ethnic disease cohorts for fine-mapping the disease-
associated regions can be a powerful approach.
Now that a plethora of CD susceptibility factors has been
identified, the challenge is to pinpoint the causal variants from
each locus, and to prove that these causal variants affect the
function of tissues and cell types involved in CD. Meeting this
challenge requires a multidisciplinary approach, involving the
generation and integration of bioinformatic, genetic, immuno-
logical and cell biological experimental data and clinical data.
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Fig. 2 History of celiac disease genetics. The final Immunochip anal-
ysis increased the number of independent non-HLA CD susceptibility
SNPs to 57 (see text for further details)
Fig. 1 Overview of the celiac disease loci. a Manhattan plot showing
the CD susceptibility loci identified by Immunochip. The x-axis dis-
plays the − log10 P values and the y-axis displays the chromosomes.
Candidate genes from 39 loci are shown in the first text column. At
three loci (IRAK1, SH2B3, and MMEL1), the most significant SNPs at
each locus are in absolute linkage with coding variants. Next, the odds
ratios (OR) of all CD SNPs are displayed. In the last column 28 CD
loci are also shown to be susceptibility regions for other autoimmune
diseases (the shared disease associations are extracted from the GWAS
catalogue (www.genome.gov/gwastudies)). AA alopecia areata, AID
autoimmune disease, ASP ankylosing spondylitis, CrD Crohn’s dis-
ease, IBD inflammatory bowel disease, MS multiple sclerosis, PBC
primary biliary cirrhosis, PSO psoriasis, RA rheumatoid arthritis, SLE
systemic lupus erythematosus, T1D type I diabetes, UC ulcerative
colitis, VL vitiligo. b Odds ratios (OR) and cumulative heritability
associated with each locus. Along the x-axis all the CD risk loci are
arranged according to decreasing OR. Multiple independent signals at
one locus are depicted as “gene name”_2 or “gene name”_3 (e.g.,
SOCS1_1, SOCS1_2, and SOCS1_3 indicate three independent signals
at the SOCS1 locus). We assumed a CD heritability of 89 % [75] and
CD prevalence of 1.5 % to estimate the cumulative heritability
explained. The OR of 12 for HLA [74] and the ORs of the non-HLA
CD loci [24] were published previously
R
Semin Immunopathol (2012) 34:567–580 571
meet this challenge, while focusing on the non-HLA CD
susceptibility loci.
Regulatory regions
Until recently, the focus of genetic studies on autoimmune
diseases has been on protein coding genes and many inves-
tigators expected to find SNPs that alter protein sequences,
and thereby protein function. One of the most surprising
findings from the recent study by Trynka et al. [24] is that
only three of the 57 independent SNPs appear to affect
protein sequences (in MMEL1, SH2B3, and IRAK1). A
careful inspection of the finely mapped loci indicates that
many SNPs map to either 5′ or 3′ untranslated regions
(UTRs), to introns, or to intergenic regions (Fig. 3a). The
RUNX3, RGS1, ETS1, TAGAP, and ZFP36L1 genes show
association with CD in the 5’-UTR region (i.e., 1st exon and
10 kb upstream of it), suggesting that the transcriptional
regulation of these genes is affected by the CD-risk SNPs.
There are different ways in which 5′-UTR SNPs can exert an
effect on transcription, for example by altering or creating
binding sites for transcription factors, or by modifying the
binding sites for chromatin-modifying protein complexes,
which in turn can affect DNA methylation and/or histone
modification (‘epigenetic effects’) [41, 42]. The association
of CD to IRF4, PTPRK, and ICOSLG seems to affect 3′-
UTR sequences which, theoretically, could lead to a de-
crease in stability or increased degradation of the respective
mRNAs, or to inhibition of translation by, for example,
altering binding sites for RNA-stabilizing/destabilizing pro-










Fig. 3 Location and effect of CD risk SNPs. a Genomic location of the
SNPs. Proxy SNPs (R2>0.8) for 57 CD top SNPs were extracted using
the 1000 Genomes Project CEU population. Only three (5 %) of the 57
SNPs were in linkage with coding variants. About 5 and 9 % are
located in the 5’-UTR and the 3’-UTR regions, respectively. This
leaves 81 % of the variants to be located in non-coding regions of
the genome (intergenic or intronic). The latter SNPs could be involved
in the regulation of gene expression or they could affect non-coding
RNA species. b Expression quantitative trait loci (eQTL) analysis at
SNP rs917997. The figure shows the association of the risk genotype
with a lower expression of IL18RAP (P01.1×10−133). The left panel
displays the distribution of the normalized expression levels of
IL18RAP mRNA according to the genotypes at rs917997. The blue
and orange dots indicate samples from male and female volunteers,
respectively. The right panel displays the foldchange in the levels of
IL18RAP mRNA.
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gene, one of the SNPs is located in a potential binding
site for hsa-miR-1910 [24]. Furthermore, the CD SNP
rs7559479 in the IL18RAP locus alters the binding efficiency
of hsa-miR-140-3p, hsa-miR-212, and hsa-mir-27a, while
another SNP in the same area (rs7603250) affects the
binding of hsa-miR-668. It is important to note that rs7559479
also creates a potential binding site for has-miR-136 (as pre-
dicted by snpinfo.niehs.nih.gov). We consider it interesting
that the IL18RAP gene displays the strongest e-QTL effect [6],
corroborating the hypothesis that miRNAs may affect the
expression of IL18RAP. Moreover, some of the CD-risk
“top-SNPs” (i.e., the SNPs with the lowest P values) show
overlap with genes encoding non-coding RNAs (ncRNAs),
such as microRNAs (miRNAs), long intergenic non-coding
RNAs (lincRNAs), or small nucleolar RNAs (snoRNAs)
(unpublished results), indicating that additional layers of
gene regulation and gene-splicing are involved in the
disease mechanism. This finding should not be surpris-
ing as about 16 % of the loci associated with complex
diseases do not harbor protein-coding genes [43, 44]. Alto-
gether, it has become clear that ~95% of the CD-risk SNPs are
located in regulatory regions (Fig. 3a). The fine mapping of
CD loci is ongoing and more light will be shed on the role of
these regions in the etiology of CD.
Expression QTL analysis can help to identify
the causative gene in a locus with multiple candidates
It is difficult to identify the causal gene in a disease-
associated locus that contains multiple candidate genes.
The fact that the disease-associated SNP may not be the
causal SNP, in strong LD with the true causal variant, it adds
to the problem of identifying the causal gene. An elegant
strategy that can be applied to narrow down the causal gene
in a locus is to correlate genotypes with expression data.
This approach has been coined expression QTL analysis
[45–47]. Although eQTL analysis does not prove that the
gene is the causal one in the locus, it can help in prioritizing
genes for follow-up studies.
eQTLs come in two flavors: (1) cis-eQTLs in which
SNPs affect expression of nearby genes [48], and (2)
trans-eQTLs in which SNPs affect the expression of genes
far away on the same chromosome or even on another
chromosome [48]. Dubois et al. [23] used a dataset consist-
ing of genome-wide gene expression data and genome-wide
SNP data of 1,469 human primary blood leukocytes to
perform an eQTL analysis in CD. They showed that 20
out of the 38 (53 %) non-HLA CD susceptibility loci they
investigated displayed significant eQTL effects. The most
impressive eQTL effect was found for SNP rs917997 in the
IL18RAP gene (P07.4×10e − 87) causing a 9-fold differ-
ence of IL18RAP expression between carriers of two wild-
type alleles versus carriers of two risk alleles [6]. This
helped to pinpoint IL18RAP as the likely causal gene in a
locus also harboring IL18R1, IL1RL1, and IL1RL2, since the
latter three did not display a cis-eQTL effect. Altogether
these findings indicate that the mechanism underlying CD is
governed by a deregulation of gene expression. Other
immune-related diseases show similar numbers of eQTLs
for disease-associated SNPs, suggesting that this is a more
general phenomenon [6]: for example, 39 out of 71 CrD loci
(55 %) show an eQTL effect [49], and 32 out of 53 T1D loci
(60 %) [15].
The identification of eQTL effects in trans (trans-eQTLs)
is much more difficult, presumably since these are more
tissue specific and cell specific [50]. Trans-eQTLs are of
interest because they implicate biological processes by link-
ing disease SNPs to the expression pattern of many genes,
thereby potentially revealing disease-associated pathways.
As an example, Fehrmann et al. [48] described the trans-
eQTL effects of 1,167 published trait- or disease-related
SNPs on gene expression in peripheral blood mononuclear
cells (PBMCs) of 1,469 unrelated individuals. Trans-eQTL
effects were observed on 113 genes, of which 46 could be
replicated in a dataset obtained from monocytes of 1,490
different individuals, and 18 could be replicated in a dataset
generated from subcutaneous adipose, visceral adipose,
liver and muscle tissue from the same replication cohort.
In addition, they identified 18 unlinked SNP pairs, associ-
ated with a single phenotype and affecting the regulation of
the same trans-gene. The fact that singular genes are regu-
lated in trans by multiple SNPs could indicate the impor-
tance of the trans-gene in the disease mechanism. In the
same study, they also found that HLA SNPs are 10-fold
enriched for trans-eQTL effects [48].
Applying pathway analysis to zoom in on gene function
and disease mechanisms
Although the GWAS approach has its shortcomings, for
instance it cannot pinpoint the causal gene in all loci, the
approaches described above can help suggest causal candi-
date genes. A significant subset of the CD susceptibility loci
can be associated with T cell biology, including REL,
TNFAIP3, THEMIS/PTPRK, ETS1, RUNX3, TLR7/TLR8,
BACH2, and IRF4 [19], but it is likely that other cell types
are affected as well. Yet another strategy that can be applied
to GWAS results is pathway analysis and quite a number of
pathway analysis tools are now publicly available [51, 52].
In some of the pathway analysis approaches, human datasets
have successfully been intersected with results obtained
from model organisms such as yeast, worms and flies, to
infer functional and physical interaction networks [53].
Pathway analysis algorithms predict pathways based on
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connections between the genes in the query list that can be
distilled from literature co-citation, gene ontology terms, co-
expression, protein-protein interaction data, possession of
common regulatory motifs or domains, tissue-specific co-
expression, subcellular co-localization, and phenotypic pro-
filing. All of these sources of information have been shown
to provide useful data on biological function. Using these
data and insights, systems biology approaches [54] can then
be applied to unravel the role of the immune system in CD.
While these approaches have so far been less often applied
in mammalian systems, the recent availability of relevant
datasets in humans and mice will facilitate such strategies.
In a recent review Wang et al. outlined the development
of pathway-based approaches for GWAS and discussed their
practical use and caveats [51]. Many of the available tools
examine whether a group of related genes in the same
functional pathway are jointly associated with a trait
of interest. Gene Relationships Among Implicated Loci
(GRAIL) is a computational tool that takes a list of GWAS
regions and predicts the likely causal gene in each locus
using information from 250,000 PubMed abstracts [55].
GRAIL can predict new loci and was successfully applied
to RA, where it identified CD28, PRDM1, and CD2/CD58
as involved in the disease [56]. Functional relationships
between genes and their products can also be obtained from
the Kyoto Encyclopedia of Genes and Genomes [57], the
Biomolecular Interaction Network Database [58], the
Human Protein Reference Database [59], the Gene Ontology
(GO) Database [60], predicted (tissue-specific) phenome-
interactome/expression networks [61, 62], the CCSB Interac-
tome Database [63], and microarray co-expression datasets
(GEMMA; http://www.chibi.ubc.ca/Gemma).
Functionally related genes tend to be co-regulated tran-
scriptionally, although the regulatory mechanisms can be
extremely complex [64]. Despite this complexity, it is fea-
sible to predict the function of a gene based on its “co-
expressed gene signature”. As an example, GEMMA was
used to acquire the gene set that is co-expressed with
PTPRK, a gene with an unknown function. Subsequently, a
commercially available pathway analysis suite—MetaCore-
GeneGO (www.genego.com/metacore.php)—was used to
search for significant enrichment terms to suggest a function
for PTPRK. The enrichment analysis suggested that PTPRK
is involved in B cell activation (Fig. 4). Although this
observation has not yet been followed up, this illustrates that
these kinds of approaches can be readily applied to generate
novel hypotheses.
When performing pathway analyses it is important to
identify the correct tissue or cell type in which the disease
gene probably operates [65]. For this, public databases such
as BioGPS [66] can be used. The generally accepted view
on CD pathogenesis is that CD is a T cell-mediated enter-
opathy in which T cells are major players in recognizing
gluten epitopes in the context of HLA alleles and inducing
Fig. 4 Co-expression analysis to predict the function of PTPRK gene.
The left panel lists the genes showing co-expression with PTPRK in at
least 15 different microarray datasets (extracted from the GEMMA co-
expression database) and depicts the presence of interactions between
those genes. The width of the lines represents the number of datasets
(ranging from 15 to 25) containing evidence for the interaction. The
right panel displays the results of an enrichment analysis performed on
the PTPRK co-expressed genes, using the MetaCore GeneGo tool (see
text). The x-axis displays significance for each of the biological pro-
cesses plotted on the y-axis
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anti-gluten T cell responses [67]. However, a BioGPS anal-
ysis using a human expression dataset [68] associates the
CD loci not only with T cells (TAGAP, TNFRSF14, CCR4,
CTLA4, UBASH3A, and CD28), but also with NK cells
(UBE2E3, RUNX3, FASLG, PTPN2, and IL18RAP), neutro-
phils (PLEK and CCR3), and B cells (BACH2, SOCS1,
POU2AF1, ICOSLG, IRF4, CIITA, ZFP36L1, and CSK)
(Fig. 5). The results indicate that this tissue- or cell-
specific approach can assist in generating new biological
hypotheses. The BioGPS results suggest a role for NK cells
in CD, while it has previously been shown that an impaired
distribution of intraepithelial NK cells induces permanent
loss of tolerance to gliadin [69] and that a deficiency of NK
cells is involved in CD [70]. On the other hand, it is possible
that the affected “NK cell genes” do not affect NK cell
function, but that they are involved in the pathology medi-
ated by intraepithelial lymphocytes (IELs) associated with
CD, as it has been reported that CD IELs are derived from
CD8 T cells but that they start expressing NK cell effector
molecules [67]. Neutrophils may cause impaired intestinal
Fig. 5 Immune cell types implied to be involved in celiac disease by
pathway analyses. Gluten molecules, the environmental trigger of CD,
are degraded into gliadins which in turn are modified by tissue trans-
glutaminase (tTG) into deamidated gliadin (da-Gliadin). The latter
peptides are presented to the immune system, resulting in activation
of various immune cell types (according to pathway analyses, see text).
For a more detailed description of the genes involved in these process-
es, see the text and reviews by Trynka et al. [14] and Abadie et al. [67].















• In vitro analysis
• Ex vivo human models
• Animal models
• Pathway analysis
Fig. 6 Summary of strategies to identify causal variants and disease
mechanisms. GWAS association signals can be followed up by meta-
analysis and/or fine-mapping to identify specific causal variants. Path-
way and eQTL analyses can be applied to prioritize the causative genes
and to generate hypotheses to explain the biological link between a
causal gene and disease. Identified causal variants and genes can in
turn be followed up by experiments by, for instance, ex vivo stimula-
tion experiments using human or animal immune cells or by experi-
ments with inflammation models in whole animals
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barrier function by inducing a chronic inflammation and
could thereby contribute to CD pathogenesis [71]. Lastly,
B cells could be involved in presenting gluten to T cell
receptors and thus contribute to the amplification of the
anti-gluten T cell response [72]. Altogether these results
suggest that this kind of pathway analysis yields clinically
relevant information about the contribution of multiple im-
mune cell types to CD pathology.
It has to be kept in mind that pathway analysis is based
on the use of databases that contain experimental data and
that the quality of this data is not equally high for every
dataset included. Moreover, these tools favor the well-
defined pathways [73] and lesser-studied genes may not be
taken into account, making it more difficult to identify lesser
known genes and pathways involved in disease etiology.
Despite these shortcomings, pathway analysis approaches
are becoming a mainstay in medical research and they have
already demonstrated their usefulness in generating new
hypotheses that can subsequently be tested.
Conclusions
Despite decades of research on CD, we still do not under-
stand the exact mechanisms underlying this disease. How-
ever, the recent GWAS and follow-up studies have started to
uncover the genetic components contributing to this disease.
Although on the genetic level immune-related diseases still
show differences in, for example, the number of disease
susceptibility loci, the effect sizes associated to each locus,
and the environmental factors involved in the various dis-
eases [10], it is also clear that there is a remarkable overlap
of susceptibility factors between various immune-related
diseases [2, 15–22]. This overlap clearly implies the in-
volvement of shared pathways in multiple autoimmune dis-
eases and, most importantly, suggests that general treatment
modalities might be feasible for some immune-related dis-
eases. However, not all of the results obtained so far can be
readily interpreted as the resolution of the SNP analyses is,
in many cases, still not high enough. Many susceptibility
loci—also shared loci—still contain multiple genes. Several
strategies can be applied to pinpoint the causal variants in
these loci (Fig. 6) and it can be expected that, in the near
future, combinations of these approaches, which involve the
integration of complex datasets containing different levels
of information, will identify novel causal variants associated
with immune-related diseases. The elucidation of these nov-
el components has immediate clinical relevance, as they can
be included in genetic-risk modeling approaches [74].
Moreover, they might represent novel biomarkers for celiac
disease, enabling physicians to diagnose all at-risk patients,
preferably before the onset of symptoms, which would
greatly reduce the overall cost to society and the burden
on patients. Most importantly, the causal variants, or other
molecules that have been identified as playing a role in
the same pathway, represent new potential therapeutic
targets, not only for celiac disease but also other autoimmune
diseases.
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